Format

Send to

Choose Destination
Hepatol Res. 2019 Nov;49(11):1256-1262. doi: 10.1111/hepr.13425. Epub 2019 Oct 25.

Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis.

Author information

1
Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.
2
Saiseikai Suita Hospital, Suita, Japan.
3
Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan.

Abstract

Non-alcoholic steatohepatitis (NASH), which is a more severe form of non-alcoholic fatty liver disease, can at least partly lead to cirrhosis, hepatocellular carcinoma, and hepatic failure. Liver transplantation is the only option for NASH cirrhosis at this time. By 2020, NASH is projected to overtake hepatitis C as the leading cause of liver transplants in the USA. There are still no approved drugs for treating NASH. Although there are approximately 196 agents of investigational NASH therapies in various stages of development, we here mainly review phase 3 drug candidates in the pipeline for NASH. The NASH space across the seven major markets of the USA, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from $618 million in 2016 to approximately $25.3 billion by 2026. However, the fact that the race to develop an effective drug against NASH has reached the home stretch, with five drug candidates (obeticholic acid, elafibranor, selonsertib, cenicriviroc, and resmetirom) in phase 3 stage of the trial, is welcome news for patients. The very earliest a NASH drug could hit the market is 2021, assuming all goes well as planned.

KEYWORDS:

cenicriviroc; elafibranor; obechicholic acid; resmetirom; selonsertib

PMID:
31495973
DOI:
10.1111/hepr.13425

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center